Healthcare Industry News: RaySearch
News Release - June 16, 2021
Accuray Expands CyberKnife(R) System Versatility with Integration of RaySearch's RayStation Treatment Planning SystemTreatment Planning for the CyberKnife System and Other Radiation Therapy Devices Can Now be Performed Using the Same Software Solution
SUNNYVALE, Calif., June 16, 2021 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today the launch of RayStation* treatment planning support for the company's CyberKnife® M6™** and S7™** Robotic, Radiotherapy Systems. RayStation helps enable clinicians to create treatment plans for the CyberKnife M6 and S7 Systems and other conventional radiation therapy devices in one unified treatment planning system (TPS), making it easier to integrate the Accuray systems within the radiation oncology department. Integration will help to improve workflows and operational efficiency. RayStation can be combined with the Accuray data management system, iDMS®, to provide a single platform for treatment planning and data integration for CyberKnife treatments.
RayStation supports the creation of treatment plans that take full advantage of the capabilities of the CyberKnife, M6 and S7 robotic SRS/SBRT systems. Similar to the Accuray Precision® TPS, some of the key features enabled by the RayStation TPS include:
- Indication-specific motion tracking and delivery adaptation with Accuray-only Synchrony® technology, which is used on the platform as a part of every treatment delivery
- Delivery of non-coplanar, isocentric or non-isocentric treatment beams from potentially thousands of different angles
- All collimator types - fixed, Iris™ Variable Aperture and the InCise™ Multileaf Collimators – for the widest range of treatments
- Fast and accurate dose calculation that enables dose adjustment in real-time
- Deformable registration and adaptive planning
"With the addition of CyberKnife planning support, RayStation becomes the first treatment planning system to support all major photon linacs. Both Radixact and CyberKnife are extremely versatile delivery platforms, and the ability to plan for these systems in parallel with conventional linacs makes it possible to easily assess which patients benefit the most from the capabilities of the Accuray systems. We are also proud to add support for CyberKnife® in RayCare* at the same time. This means that RaySearch is able to provide all the software needed in a radiation oncology clinic with Accuray treatment delivery systems," said Björn Hårdemark, M.Sc., Deputy CEO at RaySearch.
About the CyberKnife® System
The CyberKnife System with the Synchrony motion synchronization technology uses artificial intelligence (AI) to adapt radiation delivery in real-time to patient and/or tumor movement throughout the course of treatment. The system's robotic design facilitates the delivery of radiation from potentially thousands of unique angles, significantly expanding the possible positions from which radiation beams can be delivered. The more angles and points in space from which to approach the tumor, the better a physician will be able to maximize radiation dose delivered to the tumor and minimize dose to surrounding healthy tissues. The CyberKnife System is the only device capable of delivering sub-millimetric stereotactic treatments anywhere in the body with speed, efficiency and accuracy - all without the need for human intervention.
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the effect of the RayStation treatment planning system on clinicians or providers as well as their ability to integrate Accuray systems in their departments to improve workflows and operational efficiency, the company's goals and future growth potential, the company's ability to realize the anticipated benefits of its partnerships, clinical benefits of the company's technologies, patient outcomes and the company's leadership position in radiation oncology innovation and technologies. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products and those of its partners, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to effectively manage and grow its relationships with its partners; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on April 30, 2021, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
*RaySearch: Subject to regulatory clearance in some markets. Pending 510(k) clearance. Not for sale in the USA.
**CyberKnife® System: 510(k) cleared. Subject to regulatory clearance in some markets.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Unveils VOLO(TM) Ultra, the Latest Innovation for the Radixact(R) System, at ASTRO 2021
C-RAD and Accuray Sign Agreement to Enhance Radixact(R) System Breast Cancer Treatment Capabilities
French Hospital Network Unicancer Acquires Multiple Accuray Radixact(R) Systems with the ClearRT(TM) Helical Fan-Beam kVCT Imaging and Synchrony(R) Technologies